Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune-Boosting drug and vaccine aim to fight returning prostate cancer

NCT ID NCT07686380

Not yet recruiting Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 24, 2026 · Updated 13 times

Summary

This Phase II trial tests whether an immune-boosting drug (N-803) alone or combined with a vaccine (ETBX-071) can lower PSA levels in men whose prostate cancer has returned after targeted radiation therapy. Participants receive up to eight cycles of treatment and are followed for five years. The goal is to see if these therapies can control the cancer's biochemical recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
N-803 (IL-15 superagonist) and ETBX-071 vaccine
What this could lead to
If successful, this could offer a new treatment option to delay or reduce prostate cancer recurrence after radiation therapy.
What could go wrong
This is an early Phase II trial with a small number of participants. The treatment may not effectively lower PSA levels and could cause side effects from immune stimulation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER RECURRENT PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.